Lundbeck broadens phase III trial of Vyepti in children
![Photo: Thomas Borberg](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13579456.ece/ALTERNATES/schema-16_9/doc7ixmqur40g8zhmydm9u.jpg)
Children and young people who have previously participated in clinical trials of migraine drug Vyepti have now been offered the chance to remain in treatment for a longer period.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck Head of R&D denies allergy aspirations
For subscribers